Virus News and Research

Latest Virus News and Research

New development in flu prevention & treatment

In a groundbreaking development, scientists at the Australian National University in Canberra have found the key to the mutation of the flu virus. This may allow the manufacturing of a life-long vaccine stopping the need for repeated vaccinations. The scientists reveal that they have found a protein in the virus that changes or mutates in order to develop resistance in the virus.

20 Jul 2010

First Edition: July 20, 2010

Today's headlines reflect more analysis and debate regarding continuing health reform implementation efforts.

20 Jul 2010

Nontargeted opt-out screening associated with newly identified HIV-infected patients: Study

The use of routine HIV screening in a hospital emergency department, which patients had the option to decline, was associated with only a modest increase in the number of patients with newly diagnosed HIV infection, compared to physician-directed diagnostic rapid HIV testing, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

20 Jul 2010

Only 51% of HIV-exposed infants received minimal dose of prevention drug nevirapine: Study

In the ongoing battle to prevent mother-to-child transmission of human immunodeficiency virus (HIV), not all weapons are being used: Only about half of HIV-exposed infants in some African countries received a minimal dose of the prevention drug nevirapine, say researchers at the University of Alabama at Birmingham.

20 Jul 2010

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.

20 Jul 2010

NanoViricides presents study results of nanoviricides anti-Ebola agents

NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

20 Jul 2010

Study seeks patients with cancer of oropharynx to participate in Phase I clinical trial of SRS

The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with cancer of the oropharynx (back of the mouth)) to participate in a Phase I clinical trial.

20 Jul 2010

Scientists develop new way to increase effectiveness of antiviral drugs

Scientists have developed a new way to target viruses which could increase the effectiveness of antiviral drugs.Instead of attacking the virus itself, the method developed at the University of Edinburgh alters the conditions which viruses need to survive and multiply.

20 Jul 2010

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported today by the Centre for the AIDS Programme of Research in South Africa at the XVIII International AIDS Conference in Vienna, Austria.

20 Jul 2010

Scientists find major shortcomings in assessing CVD risk in HIV patients

At the same time that medical science has nearly eliminated AIDS deaths in patients treated for human immunodeficiency virus, two international meetings of HIV/AIDS scientists and patient advocates find major shortcomings in the design and analysis of studies used to assess cardiovascular disease risk in people with HIV with significant implications for improving medical care.

20 Jul 2010

Parkinson's medication produces serious side effects in the form of involuntary, jerky movements: Research

One in every 100 elderly people suffers from Parkinson's disease, a disease of the nervous system with symptoms including stiffness and shaking. The standard medication used to treat Parkinson's is Levodopa, a drug that initially has major benefits but can later also produce serious side effects in the form of involuntary, jerky movements. A research group at Lund University has now found a way to study what it is in the brain that causes these side effects.

20 Jul 2010

WHO advises earlier treatment for people with HIV

An estimated 5.2 million people were receiving life-saving HIV treatment at the end of 2009, according to the latest update from the WHO. WHO estimates that 1.2 million people started treatment in 2009, bringing the total number of people receiving treatment to 5.2 million, compared to 4 million at the end of 2008.

20 Jul 2010

BC-CfE study suggests HAART may prevent transmission, spread of HIV

The BC Centre of Excellence in HIV/AIDS published an important study today in the globally respected Lancet medical journal. The study strongly reinforces the view that the benefits of highly active antiretroviral therapy extend beyond treatment of the virus to significantly preventing the transmission and spread of HIV.

20 Jul 2010

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

"Treating HIV patients with cocktails of AIDS drugs helps to stop them spreading the infection further and more than halved the number of new HIV diagnoses in a study in Canada, scientists said on Sunday," Reuters reports.

20 Jul 2010

International organizations mutually agree to eradicate pediatric HIV/AIDS by 2015

A global alliance of international organizations, including the heads of UNICEF, UNAIDS and The Global Fund to Fight AIDS, Tuberculosis and Malaria as well as other NGOs including the Pan African Treatment Access Movement, Health GAP, Ugandan Pediatric Association and the Global AIDS Alliance today agreed to take concerted action to eliminate pediatric HIV/AIDS over the next five years, preventing nearly 400,000 children annually from beginning their lives infected with the virus that causes AIDS.

20 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

Infants in African countries receive minimum help to reduce risk of mother-to-child HIV transmission: Study

Only about half of infants born to HIV-infected mothers in some African countries receive a minimum preventive dose of the drug nevirapine to help reduce the risk of mother-to-child HIV transmission, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

20 Jul 2010

International AIDS conference focuses on HIV prevention, U.S. poverty-infection link

Speeches and studies at the international HIV/AIDS conference, now underway in Vienna, were covered by a variety of news outlets.

20 Jul 2010

Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer

Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.

19 Jul 2010

First Edition: July 19, 2010

Today's headlines include the latest news regarding the politics of implementing health reform as well as developments from the international AIDS conference now underway in Vienna.

19 Jul 2010

Virus News and Research

Latest Virus News and Research

New development in flu prevention & treatment

First Edition: July 20, 2010

Nontargeted opt-out screening associated with newly identified HIV-infected patients: Study

Only 51% of HIV-exposed infants received minimal dose of prevention drug nevirapine: Study

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

NanoViricides presents study results of nanoviricides anti-Ebola agents

Study seeks patients with cancer of oropharynx to participate in Phase I clinical trial of SRS

Scientists develop new way to increase effectiveness of antiviral drugs

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Scientists find major shortcomings in assessing CVD risk in HIV patients

Parkinson's medication produces serious side effects in the form of involuntary, jerky movements: Research

WHO advises earlier treatment for people with HIV

BC-CfE study suggests HAART may prevent transmission, spread of HIV

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

International organizations mutually agree to eradicate pediatric HIV/AIDS by 2015

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Infants in African countries receive minimum help to reduce risk of mother-to-child HIV transmission: Study

International AIDS conference focuses on HIV prevention, U.S. poverty-infection link

Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer

First Edition: July 19, 2010

A new way of characterising biomolecules eBook

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in